Understanding the Complement System’s Role in Kidney Disease
Among all challenging kidney diseases, complement system disorders account for nearly half of all cases. Most patients with kidney disease and those progressing to end-stage renal disease are under attack from their own complement system.
Over the past decade, nephrology research has significantly advanced our understanding of the complement system, leading to accelerated development of targeted therapies.
What is the Complement System?
While most people are familiar with bacteria, immune cells, and antibodies, few have heard of the complement system—and for good reason. It’s incredibly complex.
The complement system consists of over 30 different proteins with behaviors that often seem counterintuitive. These proteins contain many mysteries that continue to challenge medical students and experts alike. Even seasoned specialists may have different interpretations of how these systems work.
Fortunately, you don’t need to master these complex details. What’s important to understand is this fundamental concept:
How Does the Complement System Attack the Kidneys?
The complement system consists of proteins, mostly synthesized by the liver. At any given moment, each of us has approximately 100 billion trillion complement proteins circulating in our bodies.
Under normal circumstances, these complement proteins remain inactive. However, when bacteria invade, the complement system can activate within one second, causing proteins to split, transform, and assemble into thousands of “spear-like” structures that pierce holes in bacterial membranes.
The process works efficiently because bacterial cell membranes carry a positive charge while complement proteins carry a negative charge—opposites attract, making this attack rapid and highly effective.
Additionally, immune cells (phagocytes) normally struggle to capture bacteria because both their membranes carry negative charges, causing repulsion. However, positively charged complement proteins act like magnets, creating a negative-positive-negative chain (immune cell → complement → bacteria), making it easier for immune cells to capture and destroy bacteria.
So how does this loyal guardian of human health end up attacking the kidneys?
Scientists haven’t fully determined the exact mechanism, but the current prevailing theory suggests:
Many organisms have evolved to camouflage themselves to avoid predators—think chameleons, leaf-like butterflies, or stick insects. Bacteria employ similar tactics, disguising their membrane proteins to resemble human cells. This allows them to invade the body without triggering immune system attacks, as the immune system mistakes them for “friendly” cells.
Only after bacteria cause damage does the immune system realize the deception: “Those with this appearance are the bad guys! I’ll attack them every time I see them!” Unfortunately, kidney cells have similar protein structures on their membranes, causing complement “spears” to target kidney cells as well.
In kidney disease, these “bad guys” are called “immune complexes,” and the complement spears are known as “membrane attack complexes.”
The actual complement attack process is far more complex than described here, involving various proteins, cells, and reactions—hence the term “complexes.” However, we need to move on to discuss the 10 kidney diseases affected by this system.
10 Kidney Diseases Under Complement Attack: Improving Treatment Outcomes
Recent advances in understanding complement mechanisms and developing complement inhibitors have led to significant progress over the past decade. New complement inhibitor medications—including eculizumab, ravulizumab, iptacopan, and avacopan—are becoming available for nephrology treatment.
This month, the Kidney Disease: Improving Global Outcomes (KDIGO) organization, the world’s most authoritative kidney disease academic institution, published expert consensus guidelines on the role of complement systems in kidney diseases.
Adding complement-targeted therapy to existing treatment regimens shows two impressive 50% improvements:
- 50% reduction in proteinuria (protein in urine)
- 50% reduction in kidney function deterioration rates
The following 10 kidney diseases affected by complement attacks are showing significantly improved treatment outcomes:
1. IgA Nephropathy
In IgA nephropathy, complement proteins are activated by IgA immune complexes deposited in the mesangial region, attacking the kidneys and causing glomerular damage.
2. IgA Vasculitis Nephritis (Henoch-Schönlein Purpura Nephritis)
Also called IgA vasculitis with kidney involvement, this condition shows similar kidney pathology to IgA nephropathy. However, IgA-induced damage affects not only the kidneys but also the intestines and skin.
3. Membranous Nephropathy
The pathogenesis of membranous nephropathy begins with autoantibody production and immune complex formation, followed by complement activation and kidney damage.
4. Diabetic Nephropathy
While diabetes is the underlying cause of diabetic nephropathy, researchers have discovered that complement activation plays a role even when blood sugar is well-controlled. Recent studies show that complement proteins are present and activated in the kidneys of diabetic nephropathy patients, contributing to kidney damage.
5. Focal Segmental Glomerulosclerosis (FSGS)
In FSGS, complement proteins can be found in localized lesions (sclerotic areas) within glomeruli. Evidence of complement activation byproducts has also been detected in urine samples.
6. Lupus Nephritis
The connection between lupus nephritis and complement has long been established. Like FSGS and C3 glomerulopathy, lupus nephritis often presents with decreased serum complement levels—a sign that large amounts of complement have been consumed in kidney attacks, indicating severe inflammation and dangerous disease progression.
7. Antiphospholipid Syndrome
Similar to lupus, this is an autoimmune disease where antibodies and complement systems attack the body’s own tissues without any external invaders.
8. ANCA-Associated Nephritis
This condition involves antineutrophil cytoplasmic antibodies (ANCA) forming immune complexes that activate complement, damaging small blood vessels throughout the body and kidney capillaries.
9. Thrombotic Microangiopathy/Hemolytic Uremic Syndrome
Hemolytic uremic syndrome is one type of thrombotic microangiopathy. The names of these conditions don’t clearly reflect their underlying causes, leading the National Kidney Foundation to suggest classification based on complement involvement.
10. Membranoproliferative Glomerulonephritis/C3 Glomerulopathy
This represents the kidney disease most closely linked to complement dysfunction. The name itself reveals this connection: “C” stands for complement, and “C3” refers to complement component 3—the protein that initiates the transformation and assembly into “spear” formations. Membranoproliferative glomerulonephritis can progress to C3 glomerulopathy if left uncontrolled, and many patients have already progressed to C3 glomerulopathy by the time of diagnosis.
The Challenge and Promise
All 10 of these kidney diseases have become particularly challenging to treat due to complement involvement. Lupus nephritis, ANCA-associated nephritis, hemolytic uremic syndrome, C3 glomerulopathy, and diabetic nephropathy represent some of the most difficult-to-treat kidney diseases, with end-stage renal disease rates exceeding 50% and significant mortality rates during acute episodes.
Even the most manageable among these—IgA vasculitis nephritis—frequently relapses, creating ongoing challenges for physicians.
With the arrival of complement inhibitors and novel traditional medicine approaches targeting complement pathways, the long-term outcomes for these kidney diseases are expected to improve significantly.
Important Considerations
It’s crucial to understand that while complement proteins act as harmful weapons in kidney disease progression, they are not the root cause. Complement activation is triggered by immune complexes, placing it downstream in the disease process. Therefore, complement inhibition is not a cure-all solution.
Treatment targets positioned further downstream are closer to the actual site of damage, making them more direct and showing higher response rates. However, they’re also further from the original disease source, making it harder to achieve complete treatment discontinuation.
In other words, complement inhibition can lead to disease improvement but may not allow patients to stop treatment entirely. Even patients diagnosed early with normal kidney function may find it difficult to achieve complete recovery or medication discontinuation through complement inhibition alone—it’s not a miracle cure.
For optimal treatment outcomes, comprehensive diagnostic evaluation to identify underlying causes and combination therapy targeting upstream disease mechanisms are essential. This holistic approach, addressing both root causes and downstream effects, can maximize improvements in proteinuria and kidney function, potentially allowing some patients to achieve treatment discontinuation.
This article is for educational purposes only and should not replace professional medical advice. Consult with your nephrologist or healthcare provider for personalized treatment recommendations.
发表回复